ArticleFrontiers in surgery2026
Preoperative frailty and tumor volume as determinants of primary management strategy and outcomes in petroclival meningioma patients.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to study how patient frailty, pre-operative tumor volume, and symptom burden collectively impact primary management choice, postoperative complication rates, and outcomes in the treatment of petroclival meningiomas. Methods: We retrospectively analyzed a cohort of 73 patients diagnosed with petroclival meningiomas at Emory Healthcare from 2000 to 2022. Frailty was quantified with the 5-item modified frailty index (mFI-5). Tumor volume was measured from pre-operative MRI with 3D Slicer. Tumor-related symptoms were clustered into five domains (visual, vestibulocochlear, sensory, motor, headache) and summed into a composite Symptom Burden Score (SBS). Primary management was categorized as surgical resection versus conservative therapy (serial imaging or radiotherapy). Multivariable logistic regression evaluated predictors of treatment selection; a second model examined 30-day postoperative complications in surgical patients. Linear mixed-effects models (LMM) tracked SBS, and domain-specific generalized linear mixed-effects models (GLMM) assessed symptom resolution at 3, 6, and 12 months, controlling for both frailty and treatment approach. Sensitivity analyses dichotomized frailty (mFI-5 = 0 vs. ≥1). Significance threshold: two-sided Results: Surgically treated tumors were larger than conservatively managed lesions (median 14.3 cm Conclusions: Preoperative tumor volume and frailty jointly influence treatment approach, yet neither metric alone dictates management decision when considered together. Perioperative risk-reduction protocols may mitigate frailty-associated morbidity. While most neurologic symptoms improve within a year, frailer patients have attenuated symptomatic improvement, in addition to domain-specific differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.